Gerresheimer closed off its first quarter to February 2019 with positive growth. “Our new financial year got off to a good start” Dietmar Siemssen, CEO confirmed.

Revenue increased by 6.3% to €308.5 million, compared to €290.4 million in the prior year quarter. Sales of injection vials, ampoules and cartridges did well, as did sales of moulded glass for medicines and cosmetics. Revenues with prefillable glass syringes also increased significantly.

Capital expenditure of €16.7 million was incurred in the first quarter of 2019. This was directed mainly at an expansion of inhaler production at the Horsovsky Tyn plant in the Czech Republic, together with further additions to production capacity and the product portfolio. Other capital expenditure relates to a planned furnace repair at the moulded glass plant in Essen, Germany, as well as production plant modernisation and automation at various plants.